Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pharvaris NV - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PHVS
Nasdaq
8731
https://pharvaris.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pharvaris NV
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
- Mar 18th, 2024 10:50 am
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
- Mar 6th, 2024 11:50 am
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
- Mar 5th, 2024 11:50 am
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
- Feb 22nd, 2024 11:50 am
Pharvaris Announces Extraordinary Meeting of Shareholders
- Feb 16th, 2024 11:50 am
Pharvaris to Present at the WSAAI Annual Meeting 2024
- Jan 26th, 2024 11:50 am
Pharvaris (PHVS) Up as FDA Lifts Clinical Hold on HAE Program
- Jan 23rd, 2024 2:34 pm
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
- Jan 22nd, 2024 9:07 pm
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Jan 22nd, 2024 11:50 am
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
- Jan 5th, 2024 11:50 am
Pharvaris N.V.'s (NASDAQ:PHVS) largest shareholders are private equity firms who were rewarded as market cap surged US$578m last week
- Dec 11th, 2023 11:56 am
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
- Dec 8th, 2023 11:00 pm
Pharvaris (PHVS) Stock Up 18% on HAE Drug Meeting Study Goal
- Dec 7th, 2023 8:17 pm
Biotech Stock Roundup: EXEL Partners RCUS for Study, PHVS & EYPT Gain on Study Data
- Dec 7th, 2023 2:25 pm
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
- Dec 6th, 2023 12:02 pm
Pharvaris shares spike as drug appears to prevent symptoms of rare disorder
- Dec 6th, 2023 11:56 am
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
- Dec 6th, 2023 11:50 am
Pharvaris to Present at the GA²LEN UCARE Conference 2023
- Nov 30th, 2023 11:50 am
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
- Nov 15th, 2023 11:50 am
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
- Nov 9th, 2023 4:00 pm
Scroll